A Phase 2/3 interventional study of dupilumab and Matching Placebo in Bullous Pemphigoid, sponsored by Regeneron Pharmaceuticals. Completed at 53 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pemphigoid, Bullous with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Pemphigoid, Bullous · United States.
Among the 15 studies in Pemphigoid, Bullous with a site in United States, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 2/3, and was the 9th registered.
64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.
Browse Pemphigoid, Bullous studies →2 of the 15 studies in Pemphigoid, Bullous with a site in United States are open now. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in United States, Australia, Austria and 17 more countries
Ages 18–85
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Pemphigoid, Bullous studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 30 across 39 interventional studies indexed under Pemphigoid, Bullous.
Median enrollment 11 across the 13 interventional studies, 86 across the 2 observational. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Regeneron Pharmaceuticals has 2 studies filed under Pemphigoid, Bullous — fewer than ten, so there is no comparison to draw.
1 of the studies in Pemphigoid, Bullous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Pemphigoid, Bullous with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60).
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other Protocol Defined Inclusion/Exclusion Criteria Apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: dupilumab · Drug: Oral corticosteroids (OCS)
Drug: Matching Placebo · Drug: Oral corticosteroids (OCS)
Loading dose administered subcutaneous (SC), followed by SC once every 2 weeks (Q2W) dosing.
Also known as: Dupixent®, REGN668, SAR231893
Matching dupilumab without active substance
Prednisone or prednisolone per standard of care to obtain control of disease activity.
Percent of Participants Achieving Sustained Remission at Week 36
Sustained remission at week 36, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off oral corticosteroids (OCS) no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 36 \& (3) Absence of need for rescue therapy during 36 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 36 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.
Time frame: At Week 36
Total Cumulative Dose of Oral Corticosteroids (OCS) From Baseline to Week 36
All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the worst observation carried forward (WOCF) method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group.
Time frame: Week 36
Percent Change in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 36
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 36
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 36
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.
Time frame: Baseline, Week 36
Percent Change in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score From Baseline to Week 36
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 36
Time to First Use of Rescue Medication Up to Week 36
Participants were considered to have used rescue treatment at the time of discontinuation from the study due to lack of efficacy, treatment-related AE, or death. Participants were censored at the time of discontinuation from the study due to other reasons. Restricted mean event time and corresponding standard error (SE) are based on the Kaplan-Meier method. The restricted mean event time was calculated up to study day 253 (i.e., week 36).
Time frame: Up to Week 36
Duration of Complete Remission While Not Requiring OCS Up to Week 36
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.
Time frame: Up to Week 36
Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 36
Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 36.
Time frame: Up to Week 36
Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 36
Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 centimeters \[cm\] diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.
Time frame: Up to Week 36
Percent of Participants Who Did Not Achieve Complete Remission Before Week 36
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 36.
Time frame: Up to Week 36
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 36
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 36
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 36
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 36
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 36
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 36
Change in Autoimmune Bullous Disease Quality of Life (ABQOL) Score From Baseline to Week 36
ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 36
Change in Percent Body Surface Area (BSA) of BP Involvement From Baseline to Week 36
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 36
Change in BP180 Immunoglobulin G (IgG) Autoantibody Titer From Baseline to Week 36
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 36
Change in BP230 IgG Autoantibody Titer From Baseline to Week 36
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 36
Percent of Participants Achieving Sustained Remission at Week 52
Sustained remission at week 52, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off OCS no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 52 \& (3) Absence of need for rescue therapy during 52 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 52 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.
Time frame: At Week 52
Total Cumulative Dose of OCS From Baseline to Week 52
All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 52 completers in each treatment group.
Time frame: Week 52
Duration of Complete Remission While Not Requiring OCS Up to Week 52
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.
Time frame: Up to Week 52
Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 52
Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 52.
Time frame: Up to Week 52
Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 52
Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 cm diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.
Time frame: Up to Week 52
Percent of Participants Who Did Not Achieve Complete Remission Before Week 52
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 52.
Time frame: Up to Week 52
Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 52
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 52
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 52
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.
Time frame: Baseline, Week 52
Percent Change in BPDAI Activity Score From Baseline to Week 52
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 52
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 52
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 52
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 52
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 52
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 52
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 52
Change in ABQOL Score From Baseline to Week 52
ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 52
Change in Percent BSA of BP Involvement From Baseline to Week 52
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 52
Change in BP180 IgG Autoantibody Titer From Baseline to Week 52
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 52
Change in BP230 IgG Autoantibody Titer From Baseline to Week 52
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 52
Percent of Participants in Complete Remission and Off OCS No Later Than Week 16
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered non-responders after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Participants with missing assessment of complete remission before week 16 due to other reasons were imputed using multiple imputation.
Time frame: Up to Week 16
Percent Change in BPDAI Activity Score From Baseline to Week 16
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 16
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 16
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 16
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 16
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 16
Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 16
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
Time frame: Baseline, Week 16
Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
Time frame: Baseline, Week 16
Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 16
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.
Time frame: Baseline, Week 16
Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52
Time frame: Through Week 52
Number of Participants With At Least One Serious TEAE Through Week 52
Time frame: Through Week 52
Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52
Time frame: Through Week 52
Number of Participants With At Least One TEAE Through Week 64
Time frame: Week 52 through Week 64
Number of Participants With At Least One Serious TEAE Through Week 64
Time frame: Week 52 through Week 64
Number of Participants With At Least One TE AESI Through Week 64
Time frame: Week 52 through Week 64
Concentrations of Functional Dupilumab in Serum
Time frame: Baseline to Week 64
Number of Participants With TE Anti-drug Antibody (ADA) Response Per Maximum Titer Category
Time frame: Baseline to Week 64
Supplemental Analysis of Total Cumulative Dose of OCS From Baseline to Week 36
All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group. Median total cumulative dose of OCS from baseline to week 36 reported.
Time frame: Week 36
| Milestone | Placebo | Dupilumab Q2W |
|---|---|---|
| Started | 53 | 53 |
| Completed | 32 | 45 |
| Not completed | 21 | 8 |
| Withdrew: Adverse event | 6 | 2 |
| Withdrew: Lack of efficacy | 5 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 8 | 3 |
| Withdrew: Death | 2 | 1 |
Sustained remission at week 36, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off oral corticosteroids (OCS) no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 36 \& (3) Absence of need for rescue therapy during 36 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 36 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving Sustained Remission at Week 36 | 4.0 | 18.2 |
All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the worst observation carried forward (WOCF) method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group.
| milligrams (mg) | Placebo | Dupilumab Q2W |
|---|---|---|
| Total Cumulative Dose of Oral Corticosteroids (OCS) From Baseline to Week 36 | 5121.15 ± 473.034 | 4184.93 ± 454.733 |
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percentage of Change | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 36 | -26.7 ± 6.59 | -51.8 ± 6.66 |
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 36 | 10.5 | 39.8 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percentage of Change | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in Bullous Pemphigoid Disease Area Index (BPDAI) Activity Score From Baseline to Week 36 | -50.5 ± 7.04 | -76.7 ± 6.89 |
Participants were considered to have used rescue treatment at the time of discontinuation from the study due to lack of efficacy, treatment-related AE, or death. Participants were censored at the time of discontinuation from the study due to other reasons. Restricted mean event time and corresponding standard error (SE) are based on the Kaplan-Meier method. The restricted mean event time was calculated up to study day 253 (i.e., week 36).
| Days | Placebo | Dupilumab Q2W |
|---|---|---|
| Time to First Use of Rescue Medication Up to Week 36 | 126.8 ± 8.17 | 168.9 ± 10.96 |
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.
| Days | Placebo | Dupilumab Q2W |
|---|---|---|
| Duration of Complete Remission While Not Requiring OCS Up to Week 36 | 12.9 ± 8.08 | 38.7 ± 7.88 |
Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 36.
| Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 36 | 7.5 | 1.9 |
Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 centimeters \[cm\] diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.
| Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 36 | 91.8 | 73.1 |
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 36. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 36.
| Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Who Did Not Achieve Complete Remission Before Week 36 | 50.9 | 39.6 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 36 | 13.2 | 41.0 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 36 | 12.5 | 38.8 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 36 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 36 | 9.8 | 38.6 |
ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Score on a Scale | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in Autoimmune Bullous Disease Quality of Life (ABQOL) Score From Baseline to Week 36 | -3.41 ± 1.492 | -7.09 ± 1.458 |
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percent BSA | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in Percent Body Surface Area (BSA) of BP Involvement From Baseline to Week 36 | -17.51 ± 2.544 | -24.07 ± 2.411 |
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| units per milliliter (U/mL) | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in BP180 Immunoglobulin G (IgG) Autoantibody Titer From Baseline to Week 36 | -137.57 ± 57.125 | -136.33 ± 53.247 |
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| U/mL | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in BP230 IgG Autoantibody Titer From Baseline to Week 36 | -33.91 ± 29.380 | -18.49 ± 27.705 |
Sustained remission at week 52, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off OCS no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 52 \& (3) Absence of need for rescue therapy during 52 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 52 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving Sustained Remission at Week 52 | 4.0 | 14.2 |
All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 52 completers in each treatment group.
| mg | Placebo | Dupilumab Q2W |
|---|---|---|
| Total Cumulative Dose of OCS From Baseline to Week 52 | 7159.09 ± 820.144 | 5133.03 ± 788.414 |
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered as not achieving complete remission after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered as not achieving complete remission. Participants with missing assessment of complete remission due to other reasons were imputed using multiple imputation.
| Days | Placebo | Dupilumab Q2W |
|---|---|---|
| Duration of Complete Remission While Not Requiring OCS Up to Week 52 | 24.7 ± 15.11 | 67.2 ± 14.13 |
Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who achieved initial control of disease activity after rescue treatment use were considered to not have achieved control of disease activity before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved control of disease activity before week 52.
| Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Who Did Not Achieve Control of Disease Activity Before Week 52 | 7.5 | 1.9 |
Relapse was defined as the appearance of 3 or more new lesions a month (blisters, eczematous lesions, or urticarial plaques) or at least 1 large (\>10 cm diameter) eczematous lesion or urticarial plaque that does not heal within 1 week. Control of disease activity was defined as absence of new lesions and existing lesions beginning to heal. Participants who used rescue treatment were considered to have relapsed after achieving control of disease activity. Participants whose response status could not be determined due to missing data were considered to have relapsed after achieving control of disease activity.
| Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Who Relapsed After Achieving Control of Disease Activity Up to Week 52 | 91.8 | 76.9 |
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants who achieved initial complete remission after rescue treatment use were considered to not have achieved complete remission before week 52. Participants whose response status could not be determined due to missing data were considered to not have achieved complete remission before week 52.
| Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Who Did Not Achieve Complete Remission Before Week 52 | 50.9 | 34.0 |
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percentage of Change | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 52 | -23.4 ± 6.41 | -53.0 ± 6.44 |
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 52 | 8.3 | 36.4 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percentage of Change | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in BPDAI Activity Score From Baseline to Week 52 | -49.1 ± 7.02 | -76.1 ± 6.85 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 52 | 11.2 | 37.2 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 52 | 10.6 | 36.6 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 52 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 52 | 9.9 | 34.4 |
ABQOL questionnaire consists of 17 items, which encompass physical burden of the disease, psychiatric effects, and effects on daily life functioning. Each question ranges from 0 to 3 points, with higher scores indicating poorer quality of life. The maximum ABQOL score is 51. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Score on a Scale | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in ABQOL Score From Baseline to Week 52 | -3.27 ± 1.508 | -7.29 ± 1.465 |
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percent BSA | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in Percent BSA of BP Involvement From Baseline to Week 52 | -16.59 ± 2.588 | -23.89 ± 2.445 |
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| U/mL | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in BP180 IgG Autoantibody Titer From Baseline to Week 52 | -133.02 ± 57.248 | -137.60 ± 53.315 |
Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 52. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| U/mL | Placebo | Dupilumab Q2W |
|---|---|---|
| Change in BP230 IgG Autoantibody Titer From Baseline to Week 52 | -33.33 ± 29.392 | -18.83 ± 27.802 |
Complete remission was defined as absence of new lesions and epithelialization of old lesions. Participants were considered non-responders after rescue treatment use. Participants with missing assessment of complete remission caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Participants with missing assessment of complete remission before week 16 due to other reasons were imputed using multiple imputation.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants in Complete Remission and Off OCS No Later Than Week 16 | 26.6 | 34.6 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percentage of Change | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in BPDAI Activity Score From Baseline to Week 16 | -56.3 ± 7.02 | -78.5 ± 6.88 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥50% From Baseline to Week 16 | 45.2 | 67.3 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥75% From Baseline to Week 16 | 37.1 | 59.4 |
BPDAI activity score is the arithmetic sum of 3 subcomponents: cutaneous blisters/erosions, cutaneous urticaria/erythema, and mucosal blisters/erosions. Scores can range from 0 to 360 for BPDAI total activity (maximum 240 for total skin activity and 120 for mucosal activity), with higher scores indicating greater disease activity. Participants were required to have a BPDAI activity score of ≥24 at the screening and baseline visits for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the BPDAI activity score.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants Achieving a Reduction in BPDAI Activity Score of ≥90% From Baseline to Week 16 | 32.7 | 45.8 |
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Values after first rescue treatment were set to missing and were imputed with the worst value from the closest visit on or prior to rescue medication use and afterwards up to and including week 36. Missing values caused by discontinuation from the study due to lack of efficacy, treatment-related AE, or death were imputed by the WOCF method. Missing values due to other reasons were imputed by multiple imputation.
| Percentage of Change | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent Change in Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16 | -36.4 ± 6.30 | -50.4 ± 6.35 |
Peak pruritus NRS was used by participants to rate the intensity of pruritus during the past 24 hours, with 0 indicating no itch and 10 indicating worst itch possible. Participants were required to have a baseline peak pruritus NRS maximum intensity average of ≥4 during the 7 days prior to randomization for eligibility. Participants were considered non-responders after rescue treatment use. Participants with missing values caused by discontinuation from the study before week 16 due to lack of efficacy, treatment-related AE, or death were considered non-responders. Missing values due to other reasons were imputed using multiple imputation of the continuous data of the weekly average of daily peak pruritus NRS.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Percent of Participants With Improvement (Reduction) of Weekly Average of Daily Peak Pruritus NRS ≥4 From Baseline to Week 16 | 33.5 | 50.9 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE) Through Week 52 | 51 | 51 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Number of Participants With At Least One Serious TEAE Through Week 52 | 16 | 12 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Number of Participants With At Least One TE Adverse Event of Special Interest (AESI) Through Week 52 | 0 | 4 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Number of Participants With At Least One TEAE Through Week 64 | 23 | 25 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Number of Participants With At Least One Serious TEAE Through Week 64 | 8 | 8 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Number of Participants With At Least One TE AESI Through Week 64 | 0 | 0 |
| milligrams per liter (mg/L) | Dupilumab Q2W |
|---|---|
| Week 0 | 0 ± 0 |
| Week 4 | 50.2 ± 26.2 |
| Week 16 | 66.7 ± 47.4 |
| Week 36 | 71.0 ± 60.0 |
| Week 52 | 78.6 ± 64.3 |
| Week 64 | 8.73 ± 22.4 |
| Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| TE Maximum Titer Low (<1,000) | 0 | 1 |
| TE Maximum Titer Moderate (1,000 to 10,000) | 0 | 1 |
| TE Maximum Titer High (>10,000) | 0 | 0 |
All participants in both treatment groups were started on OCS at randomization (day 1) with taper beginning no later than week 6 with the objective to taper off by week 16. OCS could be used as rescue treatment for loss of disease control/ disease relapse during the study. Days after non-OCS systemic rescue treatment use were imputed by the WOCF method (i.e., the highest daily OCS dose prior to any non-OCS systemic rescue treatment use). Missing data after study discontinuation were imputed with the average daily OCS dose among week 36 completers in each treatment group. Median total cumulative dose of OCS from baseline to week 36 reported.
| mg | Placebo | Dupilumab Q2W |
|---|---|---|
| Supplemental Analysis of Total Cumulative Dose of OCS From Baseline to Week 36 | 4112.36 (3312.85 to 5158.25) | 2808.85 (1897.47 to 4115.00) |
Sustained remission at week 36, defined as: (1) Complete remission (absence of new lesions \& epithelialization of old lesions) \& off oral corticosteroids (OCS) no later than week 16 \& (2) Absence of disease relapse (appearance of ≥3 new lesions a month \[blisters, eczematous lesions, or urticarial plaques\] or at least 1 large eczematous lesion or urticarial plaque that does not heal within 1 week) after completion of OCS taper, no later than week 16, to week 36 \& (3) Absence of need for rescue therapy during 36 weeks (rescue therapy includes increase of OCS dose during the taper, re-initiation of OCS after completion of the OCS taper, or initiation of any BP-directed therapy). Participants with missing sustained remission data at week 36 due to discontinuation due to lack of efficacy, treatment-related AE, or death were considered non-responders \& those with missing data due to other reasons were handled using multiple imputation.
| Estimated Percentage of Participants | Placebo | Dupilumab Q2W |
|---|---|---|
| Post-Hoc Analysis of the Primary Endpoint as Per Health Authority: Percent of Participants Achieving Sustained Remission at Week 36 | 6.1 | 18.3 |
Collected over From signing of informed consent through end of study (approximately 69 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 6/53 (11.3%) | 21/53 (39.6%) | 49/53 (92.5%) |
| Dupilumab Q2W | 2/53 (3.8%) | 20/53 (37.7%) | 43/53 (81.1%) |
| Event | Placebo | Dupilumab Q2W |
|---|---|---|
| PemphigoidSkin and subcutaneous tissue disorders | 3/53 | 3/53 |
| PneumoniaInfections and infestations | 0/53 | 2/53 |
| CellulitisInfections and infestations | 2/53 | 0/53 |
| Urinary tract infectionInfections and infestations | 2/53 | 0/53 |
| AnaemiaBlood and lymphatic system disorders | 2/53 | 0/53 |
| Arthritis bacterialInfections and infestations | 0/53 | 1/53 |
| Device related sepsisInfections and infestations | 0/53 | 1/53 |
| Post procedural infectionInfections and infestations | 0/53 | 1/53 |
| Staphylococcal skin infectionInfections and infestations | 0/53 | 1/53 |
| UrosepsisInfections and infestations | 0/53 | 1/53 |
| Event | Placebo | Dupilumab Q2W |
|---|---|---|
| PemphigoidSkin and subcutaneous tissue disorders | 12/53 | 6/53 |
| NasopharyngitisInfections and infestations | 8/53 | 8/53 |
| DiarrhoeaGastrointestinal disorders | 6/53 | 8/53 |
| FallInjury, poisoning and procedural complications | 8/53 | 5/53 |
| Oedema peripheralGeneral disorders | 7/53 | 8/53 |
| Urinary tract infectionInfections and infestations | 2/53 | 5/53 |
| ConjunctivitisInfections and infestations | 0/53 | 5/53 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/53 | 5/53 |
| HeadacheNervous system disorders | 5/53 | 4/53 |
| HypertensionVascular disorders | 5/53 | 4/53 |
The full analysis set (FAS) included all randomized participants.
| Age, Continuous(Years) | Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| Mean | 71.5 ± 9.52 | 71.2 ± 10.01 | 71.3 ± 9.72 |
| Sex: Female, Male(Participants) | Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| Female | 24 | 32 | 56 |
| Male | 29 | 21 | 50 |
| Race/Ethnicity, Customized(Participants) | Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| White | 37 | 35 | 72 |
| Black or African American | 1 | 1 | 2 |
| Asian | 7 | 9 | 16 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 2 | 0 | 2 |
| Not Reported | 6 | 8 | 14 |
| Race/Ethnicity, Customized(Participants) | Placebo | Dupilumab Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 3 |
| Not Hispanic or Latino | 42 | 43 | 85 |
| Unknown | 1 | 2 | 3 |
| Not Reported | 7 | 8 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual patient data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Oct 2020 to primary completion in Jul 2024, 44 months.
Results were first posted in Mar 2026, 1 year 7 months after primary completion. A results delay was requested in Jul 2025.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab